← ANALYST RATINGS · TIPRANKS

Alector (ALEC): analyst forecast and price target

$1.84 −3.66% close 16.10.26 · market cap $213M · Healthcare · Biotechnology IWM 0.01%
Price targets and ratings of

Analyst consensus

Hold

2 Buy3 Hold2 Sell

Ratings of 7 analysts in the last 3 months

12-month forecast

$3.90+112.0% upside

Based on 7 price targets given in the last 3 months, the average target is $3.90, the highest $8.00, the lowest $1.00. The average is +112.0% from the last price of $1.84.

$2.00$4.00$6.00$8.00Jan 26AprJulOctJan 27AprJulOctHigh$8.00Average$3.90Low$1.00
Highest target $8.00 Average target $3.90 Lowest target $1.00
AnalystFirmPrice target RatingUpsideAction Date Move vs SPY
Andrew Fein★★★★★★★★★★#267 · hits 52% · avg +23.7% H.C. Wainwright $5.00 → $8.00+60.0% Buy +334.8% Reiterated 14.10.26on TipRanks 11:55 +1.6%next day +1.3%
Alec Stranahan★★★★★★★★★★#1533 · hits 52% · avg +8.4% Bank of America Securities $1.00 Sell −45.7% Reiterated 14.10.26on TipRanks 06:45 +1.6%next day +1.3%
Sean Laaman★★★★★★★★★★#446 · hits 67% · avg +17.2% Morgan Stanley $3.00 Sell +63.0% Reiterated 14.10.26on TipRanks 06:35 +1.6%next day +1.3%
Thomas Shrader★★★★★★★★★★#2198 · hits 39% · avg +6.6% BTIG $6.00 Buy +226.1% Reiterated 13.10.26on TipRanks Oct 14 06:15 −10.1%next day +1.6%
Graig Suvannavejh★★★★★★★★★★#381 · hits 48% · avg +21.6% Mizuho Securities $1.50 Hold −18.5% Reiterated 06.10.26on TipRanks Oct 7 05:20 −9.6%next day +6.3% · 5 days +3.5%
Yaron Werber★★★★★★★★★★#117 · hits 59% · avg +28.0% TD Cowen — Hold — Reiterated 05.10.26on TipRanks 10:11 +9.3%next day −9.6% · 5 days +4.1%
Myles Minter★★★★★★★★★★#92 · hits 61% · avg +34.9% William Blair — Hold — Reiterated 07.08.26on TipRanks 03:50 −3.3%next day −5.0% · 5 days +9.7%
Pete Stavropoulos★★★★★★★★★★#2065 · hits 45% · avg +16.4% Cantor Fitzgerald — Buy — Upgrade 15.04.26on TipRanks 07:05 +6.3%next day −1.4% · 5 days −6.6%

The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included

Best analysts covering Alector

TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.

Most accurate

3 months Alec Stranahan★★★★★★★★★★Bank of America Securities · #1533
Hits 52%203 of 392 Average return +8.4%
1 year Alec Stranahan★★★★★★★★★★Bank of America Securities · #1533
Hits 52%203 of 392 Average return +8.4%
2 years Alec Stranahan★★★★★★★★★★Bank of America Securities · #1533
Hits 52%203 of 392 Average return +8.4%

Most profitable

3 months Andrew Fein★★★★★★★★★★H.C. Wainwright · #267
Hits 52%257 of 494 Average return +23.7%
1 year Andrew Fein★★★★★★★★★★H.C. Wainwright · #267
Hits 52%257 of 494 Average return +23.7%
2 years Alec Stranahan★★★★★★★★★★Bank of America Securities · #1533
Hits 52%203 of 392 Average return +8.4%

How the average price target moved

The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $2.38 at a price of $1.85 (+28.4%); now: $3.90 at $1.84 (+112.0%).

$2.00$3.00$4.00Sep 15Oct 1Oct 15Top analysts$4.62Average target$3.90Price$1.84

PriceAverage targetTop analysts’ target

Recommendation trend

010206863Oct 256494Nov4113Dec365Jan 26354Feb343Mar3162Apr3162May2152Jun141Jul132Aug142Sep556Oct

Strong BuyBuyHoldSell

Rating05.2606.2607.2608.2609.2610.26
Strong Buy321115
Buy110000
Hold654345
Sell221226

Earnings and sales forecast

Next report: 10.11.26 (Q3 2026, date not confirmed)

Earnings per share

Next quarter’s EPS estimate — $-0.22 (from $-0.24 to $-0.19). Last quarter: $-0.21.

Sales

Next quarter’s sales estimate — $2M (from $0M to $5M). Last quarter: $3M.

Best top-analyst consensus in the sector · Healthcare

AXGNAxoGen
MDWDMediwound
OCULOcular Therapeutix
OVIDOvid Therapeutics
ZYMEZymeworks
About Alector
  • CEO: Arnon Rosenthal
  • Employees: 103
  • 131 Oyster Point Boulevard, South San Francisco, CA, 94080, US
  • www.alector.com

Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.

Data from the stock’s TipRanks forecast page, read 62 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗